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Abstract Chronic obstructive pulmonary disease (COPD) is a condition characterized by progressive airflow limitation, 
with symptoms of dyspnoea, cough, and sputum production. Aside from information on prevalence, mortality and hospital 
resource utilization arising from COPD in Canada, there is a lack of data on the impact of the disease on primary care 
healthcare resource utilization and the economic burden of the disease (i.e. direct and indirect costs). Canada IS not 
unusual In this respect, as surprisingly few studies have attempted to quantify the impact of COPD on the healthcare 
system and society in other countries. In an attempt to address the need for information on the burden of COPD, an 
economic analysis of data from a large-scale international survey, Confronting COPD in North America and Europe, was 
conducted in Canada and six other countriesThe results of the Canadian survey ertimated the direct cost of the disease 
at CA$l997.8 I per patient, with over half of this due to inpatient hospitalizations. COPD also had an impact on the 
economy, with indirect costs amounting to CA$I 198.18, a third of the total per patient cost of COPD to society 
(CA$3 195.97). Reducing the impact of this disease will necessitate improvements to the way the disease is managed in 
primary care, as poor symptom control and frequent exacerbations are key drivers of hospital and other unscheduled 
care costs. Early diagnosis and the application of available but underused Interventions (e.g. smoking cessation, inhaled drug 
therapies and pulmonary rehabilitation) could reduce the morbidity and costs of COPD in this country 
0 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
condition characterized by progressive airflow limitation, 
with symptoms of dyspnoea, cough, and sputum 
production.The single most important cause of COPD in 
the Western World is long-term smoking behaviour (I). 
In Canada, an estimated 750000 people have been 
diagnosed with COPD, with a prevalence rate of 2.8% in 
men and 3.6% in women over the age of 35 years (2). 
However,  these figures are likely to underestimate the 
true prevalence of the condition, as many patients with 
early symptoms of COPD do not seek contact with a 
healthcare professional, and remain undiagnosed (3). 
There is also evidence suggesting gender bias in the 
diagnosis of COPD in Canada, with fewer women being 
diagnosed than men (4). 
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As in other developed countries worldwide, COPD in 
Canada causes considerable mortality. In 1998, COPD 
was listed as the primary cause of death in almost IO 000 
patients, accounting for 4% of all deaths in this country 
(5). However,  these statistics may underestimate 
mortality rate in COPD patients.A recent study showed 
that even among patients with at least one hospitalization 
for COPD, this diagnosis was mentioned on the death 
certificate in less than 50% of cases, demonstrating that 
COPD is infrequently listed as a contributing cause of 
death in patients with this condition (6). More men than 
women currently die from COPD in Canada, reflecting 
the higher incidence of smoking behaviour among men 
over the past few decades, although the mortality rate in 
women is predicted to overtake that of men by 2005, due 
to changes in smoking habits resulting in a higher pro- 
portion of women with COPD in the aging population (5). 
COPD is a disease associated with substantial 
morbidity. In Canada, COPD is the fourth most common 
cause of hospitalization among men and the sixth most 
common cause of hospitalization among women (7). 
Almost 60000 patients were admitted to hospital with 
COPD in 1997 (5).The rate of hospitalization increases 
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with age: in 199819, the rate per 100000 patients ranged 
from 207 in men and 236 in women aged 55-59 years, to 
2765 in men and I I97 in women aged 80 years or over. 
While overall rates and the duration of hospitalization 
for COPD have been decreasing in Canada in recent 
years (probably due to changes in the delivery of 
healthcare services), the total number of hospitalizations 
has increased, as a result of the growing number of 
elderly people in the population. Based on current 
trends, hospitalization numbers will have doubled by 
2015, resulting in almost I20000 patients requiring a 
hospital stay due to COPD each year (5). 
Aside from information on prevalence, mortality and 
hospital resource utilization arising from COPD in 
Canada, there is a lack of data on the impact of the disease 
on primary care healthcare resource utilization, and the 
economic burden of the disease (i.e. direct and indirect 
costs). Canada is not unusual in this respect,as surprisingly 
few studies have attempted to quantify the impact of 
COPD on the healthcare system and society in other 
countries. To address the need for information on the 
burden of COPD, an economic analysis of a large-scale 
international survey, Confronting COPD in No&America and 
Europe, was conducted in Canada and six other countries 
(U.S.A., U.K., France, Italy, the Netherlands, and Spain).The 
survey assessed the clinical impact of COPD on the 
patient, and collected data on healthcare resource 
utilization and workplace productivity loss to calculate 
direct, indirect and societal costs of COPD in each 
country The clinical results revealed that COPD was 
underdiagnosed and undertreated, with many patients 
suffering frequent symptoms of breathlessness, coughing 
and wheezing that limited their ability to carry out 
everyday activities (8).This paper reports the results of the 
economic analysis of Confronting COPD in Canada. 
METHODS 
Survey details 
The methodology of the Confronting COPD survey has 
been described in detail elsewhere (8).The survey used 
random digit dialling of telephone numbers to 
systematically screen geographically stratified samples of 
20 I 92 I households in Canada and seven other countries 
(France, Germany, Italy, the Netherlands, Spain, the U.K. 
and the U.S.A.).Telephone interviews were conducted in 
3265 patients who reported physician diagnosed COPD, 
chronic bronchitis or emphysema, or symptoms 
consistent with a diagnosis of chronic bronchitis 
(persistent cough or sputum production for at least 
2 years). Patient responses to the survey provided data 
on clinical outcomes, inpatient hospitalizations, 
emergency room visits, primary care consultations, 
specialist contacts, treatment and laboratory tests for 
COPD, for the I2-month period prior to the survey. In 
all countries except Germany, healthcare resource 
utilization and lost productivity measures were used to 
conduct an economic analysis of the impact of COPD 
(mean direct, indirect and societal costs per patient) (9). 
A sub-analysis of costs was also conducted for patient 
groups stratified by disease severity (self-perceived or 
assessed by score on the Medical Research Council 
Dyspnoea Scale: 0-2=mild, 3d=moderate, 5zsevere) (8) 
sex, smoking status, comorbidity and education level. 
Unit costs 
Unit costs for healthcare resource use (Table I) and lost 
productivity (Table 2) in Canada were derived by local 
experts and from published sources. Unit costs for time 
lost from work were applied to patients up to the mean 
age of retirement (62.3 years for men and 60.6 years for 
women). 
RESULTS 
Patient demographics 
A total of 401 patients with physician diagnosed or 
undiagnosed COPD were included in the Canadian 
sample of the Confronting COPD survey. The 
characteristics of the patients are shown in Table 3.The 
mean age of the patient sample was 62years, with 
approximately equal numbers of men and women.Almost 
all (99.5%) of the patients were current or former 
smokers, with a mean smoking history of slightly over 
40 pack years.A quarter of the sample reported that they 
had not been diagnosed by a physician as having COPD. 
When asked about the severity of their condition, more 
than 80% of patients reported that they had mild or 
moderate COPD. When asked how well their condition 
was controlled in the past I2 months, only half of the 
patients reported that their condition was well or 
completely controlled. Over half of the patients had been 
diagnosed with comorbid conditions, including arthritis, 
heart disease, hypertension, diabetes or asthma. 
Primary and secondary care visits 
The majority (79%) of patients with COPD in the 
Canadian survey reported that they were under the care 
of a primary care practitioner (PCP). The number of 
scheduled and unscheduled PCP visits reported is shown 
in Table 4. The maximum number of unscheduled visits 
reported by any patient over the I2-month survey period 
was 20. In addition to PCP contacts, one-fifth of patients 
were also under specialist care (internal medicine, 
respiratory, allergy, cardiac or other specialists). Around 
30% of specialist contacts were unscheduled (Table 4). 
Patients reported substantial utilization of secondary 
care resources. Around 30% of patients had been 
hospitalized for COPD at some point in their lives, with 
14% of patients reporting an inpatient hospitalization 
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during the I2 months prior to the survey. Around 17% 
had visited the emergency room due to COPD, with 
over 150 visits in the past year. 
Treatment for COPD 
Almost two-thirds (62%) of the patients in the Canadian 
sample were currently receiving regular prescription 
medication for COPD. The most commonly prescribed 
drugs were inhaled corticosteroids, followed by short- 
acting &-agonists and anticholinergics (Fig. I).A minority 
of patients (I 7.5%) used a nebulizer to administer short- 
acting &-agonist or anticholinergic medication. One 
patient had been prescribed bupropion as an aid to 
smoking cessation. 
More than two-fifths (43%) of patients reported 
receiving at least one course of antibiotics for the 
treatment of respiratory infections.The mean number of 
courses taken by patients who reported antibiotic use 
was I .7, with a maximum of 24 courses taken during the 
I2 months prior to the survey. Less than two-thirds 
(63%) of patients had received an influenza vaccination 
for the prevention of respiratory infection over the past 
I2 months. A total of I0430 days of home oxygen use 
was reported by 35 patients (mean 298 days use per 
patient reporting). 
Laboratory tests 
The chest X-ray was the test most commonly reported 
for the investigation of COPD, with 349 tests received by 
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FIGURE I. Use of regular prescription medications by patients in the Canadian sample 
209 patients in the past 12 months. The maximum scan (Table 5). Overall, 829 tests were reported by the 
number of chest X-rays reported by any one patient survey sample (i.e. a mean of 2. I tests per patient). 
was 17. Two-fifths of patients reported having an 
electrocardiogram (ECG), with fewer patients receiving Work loss due to COPD 
tests of blood oxygen levels or a scan using 
computerized tomography (CT), computerized axial Around half (5 I %) of the patients in the survey sample 
tomography (CAT) or magnetic resonance imaging (MRI) were of working age. However, around 17% of patients 
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FIGURE 2. Percentage breakdown of direct per patient costs of COPD by category of healthcare resource use 
reported that COPD prevented them from attending 
work, and 12% of patients reported that their work had 
been limited by their condition. Work absence was 
reported by 6% of patients, with an estimated 4006 days 
of work loss (mean 9.99, SD 44.7 I, maximum 365 days). 
Caregiver work loss due to COPD was estimated at 
30 days for the patient sample, and was reported by 3% 
of patients in the survey. 
Direct costs 
The results of the Canadian economic analysis showed 
that the annual direct cost of COPD-related primary and 
secondary care visits, treatment and laboratory tests was 
estimated at almost CA$2000 per patient (Fig. 2, 
Table 6). Unscheduled care visits (PCP or specialist 
contacts, inpatient stays and emergency room visits) 
accounted for almost 60% of the total direct cost of 
COPD (compared with only 8% of total costs for 
scheduled care visits).The economic burden of COPD 
was particularly high in terms of inpatient care: although 
only 14% of patients reported being hospitalized in the 
last I2 months, hospital stays accounted for over half 
(52.5%) of total direct costs per patient, at an estimated 
annual cost of CA$IO49. 
Treatment for COPD accounted for over 30% of total 
direct costs in the Canadian sample, the majority of 
which was for home oxygen therapy (Fig. 2,Table 6). 
Total societal cost 
The mean cost of patient work loss due to COPD was 
estimated at CA$ I 198.18. When this indirect cost was 
added to the direct cost of COPD for the Canadian 
sample, the total societal cost of the disease was 
estimated at CA$3 195.52 per patient. Therefore, direct 
and indirect costs accounted for 62.5% and 37.5% of 
total societal costs, respectively. 
Relationship between costs and patient 
characteristics 
Further analysis of cost data from the Canadian patients 
in the Confronting COPD survey demonstrated that 
severe COPD was associated with considerably higher 
annual direct, indirect or total societal costs per patient 
than mild or moderate disease (Fig. 3). When disease 
severity was assessed in terms of score on the Medical 
Research Council (MRC) Dyspnoea Scale, the mean 
societal cost per patient with severe COPD was four 
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times higher than the cost per patient with moderate 
COPD, and I5 times higher than the cost per patient 
with mild COPD. 
Annual direct, indirect and total costs per patient with 
COPD were consistently higher in female patients than 
male patients in the Canadian sample (Table 7). 
Healthcare costs were higher in patients who were 
former smokers than current smokers, and patients with 
no education compared with those who were educated 
beyond basic schooling. Surprisingly, the mean cost to the 
healthcare system per patient with comorbid conditions 
was similar to the cost per patient without other 
illnesses. However, indirect costs per patient with COPD 
were particularly high in patients with comorbidities, and 
in current smokers. 
DISCUSSION 
The Confronting COPD survey provides an estimation 
of the utilization of primary and secondary care services 
by patients with diagnosed COPD, or symptoms 
consistent with chronic bronchitis (persistent cough with 
sputum production for 2 years or more).The survey also 
provides information on the direct and indirect costs of 
COPD. 
In Canada, the majority of patients were under the 
care of a primary care practitioner for the overall 
management of their condition, though 19% of patients 
were under the care of a specialist based in primary care 
or within a hospital outpatient department. Slightly less 
than one-fifth of patients with COPD visited the hospital 
for emergency treatment, with 14% of patients requiring 
an inpatient stay in the previous year.When unit costs of 
treatment were applied to healthcare resource use, the 
survey estimated the direct cost of the disease at almost 
CA$2000 per patient, with over half (58%) of this due to 
inpatient hospitalizations and other unscheduled care 
visits (emergency room visits, and non-routine 
appointments with healthcare professionals). In 
comparison, scheduled healthcare contacts accounted 
for only 8% of direct per patient costs. COPD has an 
impact not only on healthcare costs, but also on the 
economy in terms of lost productivity. Over 4000 days of 
work were lost by the patients in the Canadian sample, 
and indirect costs accounted for more than a third of the 
total per patient cost of COPD to society. 
THE BURDEN OF COPD IN CANADA 829 
10000 
T 
2 6000 
E 
.2 
g 6000 
5 
p 
;i 
4000 
e 
g 2000 
g 
0 
Mild Moderate 
Disease severity (self-perceived) 
Severe 
18000 
E 
16000 
5 14000 
7s 
2 
12000 
g 10000 
$ 6000 
tj 
8 6000 
E 
$ 
4000 
2000 
0 
Mild Moderate Severe 
Disease severity (MC Dyspnoea Scale) 
FIGURE 3. Direct, indirect and total societal costs by disease severity. 
The results of the survey indicate that there is 
considerable scope for reducing direct costs by lowering 
patient need for unscheduled care of exacerbations.This 
may be achieved by improving the day-to-day 
management of COPD through disease-specific 
management training for healthcare professionals (I 0). 
Special attention is needed in primary care where the 
majority of patients are treated.A barrier to the optimal 
management of COPD in primary care is underdiagnosis. 
A fifth of patients in the survey were undiagnosed, 
despite having symptoms suggesting a diagnosis of 
chronic bronchitis. Lack of diagnosis may be due to the 
poor recognition of early COPD among physicians. 
Supporting this explanation, a recent Canadian survey 
revealed that, when presented with a hypothetical case of 
middle-aged smoker with a recent upper respiratory 
tract infection and a persistent productive cough, 
physicians were slow to investigate a possible diagnosis 
of obstructive airways disease, and underutilized 
spirometry (the gold standard diagnostic test for COPD) 
as a screening tool (I I). The importance of early 
diagnosis is outlined by the findings of the current survey, 
in which costs increased markedly with the severity of 
COPD, with a l5-fold difference between the total 
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societal costs of mild and severe disease. Smoking 
cessation is the only intervention that has been shown to 
prevent the progression of the disease. Early diagnosis 
could allow the targeting of smoking cessation support 
at patients in the initial stages of COPD, thereby 
preventing progression to the more costly and disabling 
disease stages. 
The results of the Canadian survey indicated that 
patients with COPD, despite having symptoms of 
dyspnoea, were not being treated. Only half of the 
respondents thought that their condition was well 
managed with current medication. Although treatment 
guidelines recommend an annual influenza vaccination 
for the prevention of COPD exacerbations (I), almost 
40% of patients surveyed had not received a vaccination 
in the past year. Indeed, many patients suffered 
exacerbations of COPD, as shown by the number of 
patients receiving antibiotics for respiratory infections. 
Therefore, interventions aimed at improving symptoms 
and preventing exacerbations could play an important 
role in reducing the direct cost of COPD. 
Treatment of COPD has tended to focus on regularly 
administered short-acting bronchodilators, which have 
been shown to improve lung function and day-to-day 
symptoms of breathlessness (12). One-third (33%) of 
patients in the current survey reported receiving an 
inhaled short-acting &agonist. However, these 
medications have minimal effectiveness in preventing 
exacerbations of COPD.The introduction of long-acting 
bronchodilators has been shown to improve quality of 
life and reduce the frequency of mild exacerbations in 
patients with COPD (13-14) and two recent studies 
have shown that inhaled corticosteroids can reduce the 
frequency of moderate and severe exacerbations of 
COPD ( I 5-I 6). However, only 9% and 37% of patients in 
the Canadian survey sample reported the use of long- 
acting &agonists and inhaled corticosteroids, 
respectively. As the current survey did not provide 
enough information to assess the appropriateness of the 
medications prescribed, data from additional studies are 
required to establish which interventions are likely to be 
most effective in the care of patients with this disease. 
The Confronting COPD survey in Canada provided 
information on relationships between costs and patient 
characteristics. As might be expected, patients with 
severe disease were associated with higher costs than 
patients with mild disease. Patients with comorbid 
conditions were associated with similar healthcare costs 
than patients without comorbidities, although total 
societal costs were particularly high in patients with 
comorbidities. Females patients had consistently higher 
costs than male patients, which may be due to gender 
differences in the management of COPD in Canada (4) 
(however, further studies would be required to confirm 
this relationship). Finally, healthcare costs were higher in 
patients who were former smokers than current 
smokers. This may be because patients with severe 
disease (who are more costly to the healthcare system 
and society) may be more likely to stop smoking (as a 
result of ill-health) than patients with mild disease. 
Studies like the current survey have limitations. The 
telephone sampling method used to select participants 
from the survey is likely to gain a representative sample 
of patients from the general population, as most people 
in Canada have a telephone at home. However, data 
collection relied essentially on self-report, depending on 
the accuracy of patient recall with respect to variables 
such as comorbid conditions, medication and health 
service use. Similarly, the inclusion of patients with 
COPD was based on self-reported physician-diagnosed 
COPD, or symptoms consistent with the clinical 
definition of chronic bronchitis. Diagnosis could not be 
confirmed with lung function assessment.To increase the 
probability that patients included in the survey did have 
COPD, they had to be over 45 years of age with a long- 
term history of smoking behaviour (at least IO pack 
years), and no previous diagnosis of asthma (8). 
Another factor that may have been affected by the 
absence of lung function assessment is the grading of 
COPD by severity. However, the survey assessed this 
according to the degree of dyspnoea experienced by the 
patient, using a validated instrument (I 7). As COPD 
symptoms are likely to be a major driver of healthcare 
resource use and lost productivity (and therefore direct 
and indirect costs), the measurement of dyspnoea is 
likely to be a useful means of categorizing disease 
severity for economic analyses (particularly sub-analyses 
of costs in patients with mild, moderate and severe 
disease, as conducted here). 
CONCLUSION 
COPD places a significant burden on the healthcare 
system and society in Canada. Reducing the impact of the 
disease will necessitate improvements to the way the 
disease is managed in primary care: poor symptom 
control and frequent exacerbations are key drivers of 
hospital and other unscheduled care costsThe results of 
the Confronting COPD survey suggest that early 
diagnosis, and the application of available but underused 
interventions (e.g. smoking cessation, inhaled drug 
therapies and pulmonary rehabilitation) could reduce the 
morbidity and costs of COPD in this country. 
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